FLC
RVNC

Fifth Lane Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fifth Lane Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$156K – 63
2024
Q3 		$156K Buy
+30,000
New +$149K 0.39% 28

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Fifth Lane Capital's RVNC Position: Q4 2024 in Review

Fifth Lane Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 30,000 shares — an estimated $156K sold.

Fifth Lane Capital first reported a position in RVNC in Q3 2024 and held it in 1 quarter. The position peaked at $156K in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Fifth Lane Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Fifth Lane Capital sold 30,000 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $156K.
  • Fifth Lane Capital first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 1 quarter.
  • Fifth Lane Capital's Revance Therapeutics, Inc. position peaked at $156K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Fifth Lane Capital's 13F filing for Q4 2024, filed 14 Feb 2025.